Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Increases By 462.1%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 736,300 shares, a growth of 462.1% from the January 31st total of 131,000 shares. Approximately 5.9% of the shares of the stock are short sold. Based on an average trading volume of 1,410,000 shares, the short-interest ratio is presently 0.5 days.

Cyclo Therapeutics Price Performance

NASDAQ CYTH traded down $0.01 during trading on Friday, hitting $0.76. 46,810 shares of the company’s stock traded hands, compared to its average volume of 2,328,359. The stock has a fifty day moving average of $0.77 and a two-hundred day moving average of $0.76. Cyclo Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.79. The firm has a market cap of $25.02 million, a P/E ratio of -0.84 and a beta of -0.49.

Institutional Trading of Cyclo Therapeutics

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Two Sigma Securities LLC purchased a new stake in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned 0.15% of Cyclo Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 68.55% of the company’s stock.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.